152 related articles for article (PubMed ID: 12574367)
1. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells.
Xia J; Tanaka Y; Koido S; Liu C; Mukherjee P; Gendler SJ; Gong J
J Immunol; 2003 Feb; 170(4):1980-6. PubMed ID: 12574367
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
3. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
4. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody.
Pilon SA; Piechocki MP; Wei WZ
J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306
[TBL] [Abstract][Full Text] [Related]
6. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
8. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
Ercolini AM; Machiels JP; Chen YC; Slansky JE; Giedlen M; Reilly RT; Jaffee EM
J Immunol; 2003 Apr; 170(8):4273-80. PubMed ID: 12682262
[TBL] [Abstract][Full Text] [Related]
11. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
12. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
Koido S; Tanaka Y; Chen D; Kufe D; Gong J
J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
14. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
Lewis JD; Shearer MH; Kennedy RC; Bright RK
Cancer Res; 2005 Apr; 65(7):2938-46. PubMed ID: 15805297
[TBL] [Abstract][Full Text] [Related]
15. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
16. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
18. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
Yu P; Lee Y; Wang Y; Liu X; Auh S; Gajewski TF; Schreiber H; You Z; Kaynor C; Wang X; Fu YX
J Immunol; 2007 Aug; 179(3):1960-8. PubMed ID: 17641063
[TBL] [Abstract][Full Text] [Related]
19. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]